GNMX News and Press, Aevi Genomic Medicine Inc. From 07/15/19

Nano cap Aevi Genomic Medicine (NASDAQ: GNMX ) is up  23%  after hours on the heels of its exclusive in-license agreement with Astellas Pharma ( OTCPK:ALPMF ) unit OSI Pharmaceuticals securing global development and commercialization rights to ASP7486 (formerly OSI-027). More n...

PHILADELPHIA , July 15, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX, "Aevi") today announced it has entered into an exclusive license agreement with OSI Pharmaceuticals, LLC, an indirect wholly-owned subsidiary of Astellas Pharma Inc. ("Astellas") for the worldwide deve...

CORAL GABLES, FL / ACCESSWIRE / March 12, 2019 / The healthcare stock market is comprised of innovative companies working diligently to design, manufacture, and commercialize state-of-the-art tech-driven solutions for the healthcare industry. As we've seen in recent years, companies are te...

NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Park Hotels & Resorts Inc. (NYSE:PK), Planet Fitness, Inc. (NYSE:PLNT), Ae...

Aevi Genomic (NASDAQ: GNMX ): Q3 GAAP EPS of -$0.12. More news on: Aevi Genomic Medicine, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

PHILADELPHIA , Nov. 1, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the "Company") announced today financial and operational results for the three months ended September 30 , 2018 and provided an overview of the Company's recent corporate progress. Thir...

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amtech Systems, Inc. (NASDAQ:ASYS), Neos Therapeutics, Inc. (NASDAQ:NEOS)...

Thinly traded nano cap Aevi Genomic Medicine ( GNMX +1.9% ) is up on below-average volume following its announcement that Part B of its Phase 2 ASCEND study evaluating AEVI-001 in pediatric and adolescent patients with attention deficit hyperactivity disorder (ADHD) is now fully enrolled...

PHILADELPHIA , Oct. 15, 2018 /PRNewswire/ --  Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) today announced that it has reached full enrollment of Part B of its Phase 2 ASCEND clinical trial.  The ASCEND trial is a genomically-guided study in pediatric and adolescent...